While neither GCGR antagonism nor agonism are currently being explored as monotherapeutic options for the treatment of T2D or other metabolic conditions, ongoing efforts are focused on understanding how the beneficial aspects of GCGR agonism can be harnessed in combination with incretin therapies for more efficacious treatment options. Here, GCGR is linked to type 2 diabetes mellitus.